| Popis: |
In vitro, ivermectin, an anti-parasitic drug licenced by the US Food and Drug Administration, was found to limit the replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).The three groups had similar clinical symptoms of fever, cough, and sore throat. When compared to the placebo group, virological clearance was faster in the 5-day ivermectin treatment arm (9.7 days vs 12.7 days p = 0.02), but not in the ivermectin Plus doxycycline arm (11.5 days p = 0.27). In the research, there were no serious adverse medication reactions. Adult patients with mild COVID-19 were treated with a 5-day course of ivermectin, which was proven to be both safe and efficacious. To corroborate these early findings, larger trials will be required. |
